Two-year ORIGIN 3 data show Trutakna held kidney function nearly steady in IgA nephropathy. What it means for patients, coverage, and approval.
IgA Nephropathy Patients on Trutakna Kept Kidney Function Nearly Steady for Two Years While Placebo Group Declined
by | Sep 17, 2026 | Uncategorized | 0 comments

Recent Comments